Charles Senteio

Friday, April 07, 2006

Color, Medicine and Trust

My buddy Sean Hudson, who works for Pfizer in their H.I.V. Marketing organization, recently sent me a story about how the pharmaceutical company Schering-Plough is being criticized because they have purposely excluded Blacks from the early stages of clinical trials for their new hepatitis C virus (HCV) protease inhibitor, SCH 503034.

In general people of color do not trust ‘the man’… whether that man represents the government, medicine, education, or business. Of course we don’t have to look very far back in history to understand where those fears may come from. However with medicine this mistrust can be more damaging. If I don’t trust my government I may not vote and avoid police. If it don’t trust the education system I won’t embrace the curriculum and will perhaps drop out of school. If I don’t trust the business community I’ll be cynical about how companies are only in business to exploit me and I’ll begrudgingly work for them only if my lack of options mandate it. However if I don’t trust medicine or health care in general I could die earlier than I have to. I could also influence my Black friends and family to avoid interventions that could prolong their life. Granted there is good reason not to trust medicine. The Tuskegee Experiment was a 40 year 'study' sponsored by the US Public Health Service where they ‘experimented’ on 400 Black men in the deep south to see how late stages of untreated syphilis impacted them. Their scientists essentially withheld treatment and information from their subjects to sit back and observe how syphilis progresses in Black men. They told them they had 'bad blood' and didn't offer any clue as to what they were up to. This remains the shining example as to why people of color do not (should not?) trust medicine.

A recent University of Houston study published in the March Journal of Acquired Immune Deficiency Syndromes reported 30% of Texas African Americans and 22% of Texas Latinos believe HIV is a government conspiracy to kill minorities.

Schering-Plough maintains that its recruiting practices for its clinical trials are legit, their spokesman Robert Cansalvo argues because Blacks are known to respond poorly to one of the drugs SCH 503034 is being tested with that including them in the early trials is ‘unnecessary' and that they will definitely be in the next round of trials. Says Cansalvo, “It’s a question of timing when to include them.”

Some HCV scientists and activists agree that their approach to selecting subjects is sound and Schering-Plough should proceed so that this potentially valuable product moves closer to becoming available to those in need. However critics from community based organizations to Hep C advocacy organizations see their selection practices as an egregious disservice to Blacks who are in the most need. HCV is three times more common among Blacks than among Whites. Cure rates are lower for Blacks on existing meds and Blacks are more susceptible to complications of HCV like liver cancer, liver failure, and cirrhosis, all of which can lead to death.

This is a tough issue. It is a bit unsettling that Blacks are excluded from the early stages of a clinical trial for a drug that could address a virus that disproportionally impacts them. Also these protests and bad press do nothing but fan the flames of mistrust that many people of color have regarding the medical establishment.

I understand the urgent need to develop, test, and bring to market drugs that will treat some of our most pressing viruses, and diseases they cause, to market. I also understand this work is done against a backdrop of fear and mistrust.

Given both these factors I think Schering-Plough is wrong here. I don’t have a problem with the exclusion in the early stages, they seem to have solid clinical rationale here. I do think they could be more sensitive to the context in which they operate and should proactively reach out to the advocacy groups and other organizations who question their selection and work with them to explain, and discuss, why their selection rationale makes sense and their selection plans for future stages of their trial.

Their work is too important, and the scars are too deep, to ignore history and these important issues around trust that are still with us all.

30% of Texas African Americans and 22% of Texas Latinos believe HIV is a government conspiracy to kill minorities.

9 Comments:

  • Actually, we were included ...
    http://www.schering-plough.com/schering_plough/news/release.jsp?releaseID=576149

    By Anonymous Anonymous, at 1:37 PM  

  • Anonymous,
    Thanks for the insights!
    Others,
    This 'anonymous' post is from a good friend, a Black female, who has the HCV. She participated in this Schering-Plough study referenced in the link. This seems to conflict with the story however I am doing some digging. I am guessing the protests must be for another study. Will continue to investigate...

    By Blogger Charles Senteio, at 7:54 PM  

  • There were certain "myths" that were at play for why there were not that many AA's included in this study, one of which is that historically we do not seek medical assistance or follow the treatment thru to the end when it is provided. Some of this is true, but I know that all of the patients Dr. McCone (who btw is AA) treated that were AA's follwed the instructions to the letter. There was one patient that he said just couldn't handle the side effects of the meds, but the majority of us did fine. The doctors also speculated that AA's of lighter complexion would respond to the treatment better than AA's of darker complexion. Well, this speculation was proven wrong b/c I did not respond well to the meds, and I am of a much lighter complexion than some of this other patients that were treated successfully.
    There is so much to understand about this disease and how/why it effects the races so differently. I think the studies for us are going to dig a lot deeper than previous studies have up to this time.
    But a word of advise for any woman: If you insist upon getting your fingernails done, please take your own equipment. Dr. McCone said the majority of the women he treats have some of the most beautiful hands ... It's the first thing he checks on any new female patient, but I guess it can hold true to for any man who chooses to get his hands manicured.

    By Anonymous Anonymous, at 1:47 PM  

  • Thanks for the insights on the study, especially useful from someone living with HCV and who actually participated in the trial. I also appreciate the insights on the 'cost' of nice hands. Take good care.

    By Blogger Charles Senteio, at 5:59 PM  

  • I'm part of the 30%.I don't trust the the government. I believe that AIDS is a conspiracy.I beleive that the pharmaceutical industry has an investment in Capital Hill and vice-versa.I'm happy to hear that our people aren't being used as guinea pigs...as much.Companies are putting out unsafe drugs and want to test them out on any one who wants to be "compensated for their time."My grandfather had a stroke after using Vioxx for 2 months.It was not an approved drug.I know that our people have health issues that need to be addressed.I don't know if these studies are helping us.

    By Anonymous Anonymous, at 1:54 AM  

  • Tamika,
    Thanks for visiting and thanks for sharing your point of view on a very important and emotional topic. I’m also sorry to hear of your grandfather’s stroke.
    I’ve heard the conspiracy theories and do not by any means completely discount them, however I do disagree that AIDS was created and specifically targeted for peoples of color.

    However as the old saying goes, “Just because I’m paranoid, doesn’t mean people aren’t after me”

    There are larger issues here with respect to trust which you’ve captured very eloquently, “I don’t trust the government.” Unfortunately you are certainly not alone with that point of view. From issues around lobbyists and their influence in Capital Hill, to WMDs, to police on the local level many groups have issues with government entities. As I mention in this blog I do think that mistrust of health care is particularly insidious because it can and does cost people of color, and other groups, precious healthy days alive.

    By Blogger Charles Senteio, at 2:44 PM  

  • Food for thought...

    http://www.msnbc.msn.com/id/12636315/

    By Blogger Fighting Father, at 2:39 PM  

  • Boynes,
    Thanks for the link http://www.msnbc.msn.com/id/12636315/ this is a serious issue for "Big Pharma" and I'll forward along to Sean at Pfizer. Thanks!

    By Blogger Charles Senteio, at 12:10 PM  

  • Here is some additional info Sean sent me:

    Subject: FDA letter re: Schering-Plough's Initial Exclusion of African Americans from Phase II Study of HCV Protease Inhibitor

    Dear Colleagues,

    Attached and copied below is a letter that was sent to the FDA yesterday from Community HIV/AIDS Mobilization Project (CHAMP), Harm Reduction Coalition, Hepatitis C Action & Advocacy Coalition (HAAC), Hepatitis C Multicultural Outreach, and Treatment Action Group. It regards Schering-Plough's decision to initially exclude African Americans from the company's Phase II study of SCH 503034, an experimental Hepatitic C protease inhibitor.
    If you have any questions or comments, please feel free to contact me.
    Thanks,
    James

    James Learned
    Hepatitis C Action & Advocacy Coalition (HAAC)
    (718) 369-3779
    Home
    (917) 620-0349 Cell
    Email: James_Learned@prodigy.net
    =============================================================
    April 20th 2006
    Dr. Debra B. Birnkrant

    DHHS/FDA/CDER/OND/OAP/DAV

    Director, FDA Division of Antiviral Products

    White Oak CDER Office Building 22

    10903 New Hampshire Avenue

    Silver Spring MD 20993



    Dear Dr. Birnkrant,



    We are writing to express outrage about the exclusion of African Americans from Schering-Plough's phase II trials of SCH 503034, an investigational hepatitis C protease inhibitor. Study NCT00160521 is evaluating multiple doses of SCH 503034 in combination with Peg-Intron, with and without ribavirin, in people with hepatitis C who did not respond to prior treatment. The exclusion began at the time of study initiation in September 2005 and continued until March 2006, when the protocol was amended to create an additional dosing arm that permitted African Americans to enroll. However, the amendment does not remedy the fundamental problems with Schering's study design.

    Schering-Plough's initial exclusion of African Americans - the highest-prevalence population in the United States - as scientifically unjustified and ethically unacceptable. A hallmark of clinical research is the principle that each prospective research participant should have the opportunity to make an informed decision about the relative risks and benefits of participating in a clinical trial.

    We cannot overemphasize the importance of obtaining a complete picture of the relative safety and efficacy of SCH 503034 and other experimental therapies in African Americans, including during early stages of research when safety, dosing, and pharmacokinetics/ pharmacodynamics are explored. Higher prevalence of hepatitis C and suboptimal response rates to current treatment among African Americans make it incumbent upon pharmaceutical sponsors of novel therapies to design trials that provide sufficient data at the time of licensure about how drugs perform in the people most likely to use them. Registration trials of pegylated interferon failed to produce this data due to low enrollment of African Americans. As a result, African Americans with hepatitis C and their clinicians were forced to make decisions about the relative risks and benefits of treatment based on inadequate information. This scenario must not be allowed to recur with promising new agents currently in, or soon to enter, clinical trials.

    Relevant and timely data on Schering's 503034 can only be generated by enrolling adequate numbers of African Americans in phase III trials to power statistically meaningful subgroup analyses of response to treatment by race. We ask that FDA strongly encourage Schering to address this issue in its communications with the company, request and review detailed plans for statistical analysis and recruitment, and, if necessary, recommend changes in the phase III program as appropriate. Relegating research on African Americans and SCH 503034 to a later post-marketing commitment would represent a gross failure and injustice on the part of both Schering-Plough and the FDA.

    Finally, Schering's exclusion of African Americans from study NCT00160251 must not set a precedent for future trials of other investigational agents. We request that the FDA work with companies pursuing new hepatitis C therapies on designing robust development programs capable of generating clear profiles on the relative safety and efficacy of these agents in African Americans. We urge the FDA to advise sponsors that any neglect of their responsibilities to African Americans with hepatitis C will be reflected in the drug's labeling at the time of approval.



    We will convey these concerns to Schering-Plough and other companies involved in hepatitis C drug development, and look forward to a productive dialogue with FDA on this crucial issue.



    Sincerely,



    Community HIV/AIDS Mobilization Project (CHAMP)
    594 Broadway
    Suite 700
    New York, NY 10012

    http://www.champnetwork.org/



    Harm Reduction Coalition

    22 West 27th Street, 5th Floor

    New York, NY 10001

    http://www.harmreduction.org



    Hepatitis C Action and Advocacy Coalition (HAAC)

    53 Divisadero Street

    San Francisco, CA 94117-3210

    HAAC_SF@hotmail.com



    Hepatitis C Multicultural Outreach

    10603 Blue Ridge Blvd

    Kansas City, MO 64134

    www.hepcmo.org



    Treatment Action Group

    611 Broadway, Suite 608

    New York, NY 10012

    www.treatmentactiongroup.org

    By Blogger Charles Senteio, at 7:19 PM  

Post a Comment

<< Home